REGN is now in the
S&P 500

Regeneron is a science-driven large capitalization biotechnology company. Learn more here.

Meet Evans W., featured in
the Annual Report

2012 Annual Report [PDF]

Attend

Attend the Annual Meeting of Shareholders June 14, 2013.
See Upcoming Events, below, for details.

	2012 Annual Report (HTML)
	2012 10-K

Shareholder Briefcase

Download Library

Download Library

View all releases Recent Press Releases
Jun 6, 2013	Regeneron and Bayer Report Positive Phase 3 Results for EYLEA® (aflibercept) Injection in Myopic Choroidal Neovascularization (mCNV)
May 21, 2013	Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
May 15, 2013	Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)

View all events & presentations Recent Events
Jun 14, 2013	Regeneron Annual Shareholders Meeting
Jun 11, 2013	Goldman Sachs 34th Annual Global Healthcare Conference
Jun 3, 2013	Jefferies 2013 Healthcare Conference View Presentation

Short Cuts
SEC Filings

Close Window

Form content here please :)